AVDL
Income statement / Annual
Last year (2023), Avadel Pharmaceuticals plc's total revenue was $27.96 M,
and the percentage change from the previous year is not available.
In 2023, Avadel Pharmaceuticals plc's net income was -$160.28 M.
See Avadel Pharmaceuticals plc’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$27.96 M
|
$0.00
|
$0.00
|
$22.33 M
|
$59.22 M
|
$103.27 M
|
$172.74 M
|
$150.25 M
|
$173.21 M
|
$14.78 M
|
| Cost of Revenue |
$846,000.00 |
$1.49 M |
$815,000.00 |
$5.74 M |
$12.13 M |
$17.52 M |
$16.30 M |
$13.25 M |
$10.92 M |
$3.38 M |
| Gross Profit |
$27.12 M |
-$1.49 M |
-$815,000.00 |
$16.59 M |
$47.09 M |
$85.75 M |
$156.44 M |
$137.00 M |
$162.29 M |
$11.39 M |
| Gross Profit Ratio |
0.97 |
0 |
0 |
0.74 |
0.8 |
0.83 |
0.91 |
0.91 |
0.94 |
0.77 |
| Research and Development
Expenses |
$13.26 M
|
$20.70 M
|
$17.10 M
|
$20.44 M
|
$32.92 M
|
$39.33 M
|
$34.22 M
|
$34.61 M
|
$25.61 M
|
$17.30 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$100.36 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$151.71 M
|
$74.52 M
|
$68.50 M
|
$32.41 M
|
$30.18 M
|
$100.36 M
|
$58.86 M
|
$44.18 M
|
$21.71 M
|
$15.70 M
|
| Other Expenses |
$0.00 |
$3.35 M |
$217,000.00 |
$406,000.00 |
$816,000.00 |
$1.90 M |
$2.09 M |
-$6.55 M |
$0.00 |
-$36,000.00 |
| Operating Expenses |
$164.97 M |
$95.22 M |
$85.60 M |
$53.25 M |
$63.92 M |
$146.31 M |
$96.74 M |
$92.68 M |
$59.88 M |
$44.75 M |
| Cost And Expenses |
$165.81 M |
$95.22 M |
$85.60 M |
$59.00 M |
$76.04 M |
$163.82 M |
$113.04 M |
$105.93 M |
$70.81 M |
$48.13 M |
| Interest Income |
$0.00 |
$11.12 M |
$2.13 M |
$12.59 M |
$1.07 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$963,000.00 |
| Interest Expense |
$9.89 M |
$12.34 M |
$9.94 M |
$12.99 M |
$12.48 M |
$10.62 M |
$1.05 M |
$963,000.00 |
$6.30 M |
$9.27 M |
| Depreciation &
Amortization |
$1.77 M
|
$1.49 M
|
$815,000.00
|
$1.69 M
|
$2.49 M
|
$7.43 M
|
$4.88 M
|
$14.49 M
|
$13.13 M
|
$14.14 M
|
| EBITDA |
-$149.13 M
|
-$97.60 M
|
-$84.78 M
|
-$34.97 M
|
-$23.61 M
|
-$95.15 M
|
$65.89 M
|
$5.73 M
|
$115.54 M
|
-$94.74 M
|
| EBITDA Ratio |
-5.33 |
0 |
0 |
-1.42 |
-0.24 |
-0.51 |
0.37 |
0.39 |
0.67 |
-1.24 |
| Operating Income Ratio
|
-4.93
|
0
|
0
|
-1.64
|
-0.28
|
-1.02
|
0.51
|
-0.03
|
0.41
|
-6.35
|
| Total Other
Income/Expenses Net |
-$22.93 M
|
-$12.88 M
|
-$7.60 M
|
-$10.90 M
|
-$14.47 M
|
-$8.27 M
|
$3.16 M
|
-$4.75 M
|
$6.26 M
|
$3.33 M
|
| Income Before Tax |
-$160.78 M |
-$111.44 M |
-$93.15 M |
-$5.08 M |
-$38.58 M |
-$113.20 M |
$91.47 M |
-$9.72 M |
$78.39 M |
-$90.33 M |
| Income Before Tax Ratio
|
-5.75
|
0
|
0
|
-0.23
|
-0.65
|
-1.1
|
0.53
|
-0.06
|
0.45
|
-6.11
|
| Income Tax Expense |
-$501,000.00 |
$26.03 M |
-$15.82 M |
-$12.11 M |
-$5.36 M |
-$17.89 M |
$24.22 M |
$31.56 M |
$37.74 M |
-$1.41 M |
| Net Income |
-$160.28 M |
-$137.46 M |
-$77.33 M |
$7.03 M |
-$33.23 M |
-$95.30 M |
$67.25 M |
-$41.28 M |
$40.66 M |
-$84.91 M |
| Net Income Ratio |
-5.73 |
0 |
0 |
0.31 |
-0.56 |
-0.92 |
0.39 |
-0.27 |
0.23 |
-5.75 |
| EPS |
-2 |
-2.29 |
-1.32 |
0.13 |
-0.89 |
-2.55 |
1.66 |
-1 |
1 |
-2.34 |
| EPS Diluted |
-2 |
-2.29 |
-1.32 |
0.13 |
-0.89 |
-2.55 |
1.61 |
-1 |
0.93 |
-2.34 |
| Weighted Average Shares
Out |
$80.17 M
|
$60.09 M
|
$58.54 M
|
$53.00 M
|
$37.40 M
|
$37.33 M
|
$40.47 M
|
$41.25 M
|
$40.58 M
|
$36.21 M
|
| Weighted Average Shares
Out Diluted |
$80.17 M
|
$60.09 M
|
$58.54 M
|
$54.94 M
|
$37.40 M
|
$37.33 M
|
$41.77 M
|
$41.25 M
|
$43.62 M
|
$36.21 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
